AU2018255935B2 - 6-pyrimidin-isoindole derivative as ERK1/2 inhibitor - Google Patents

6-pyrimidin-isoindole derivative as ERK1/2 inhibitor Download PDF

Info

Publication number
AU2018255935B2
AU2018255935B2 AU2018255935A AU2018255935A AU2018255935B2 AU 2018255935 B2 AU2018255935 B2 AU 2018255935B2 AU 2018255935 A AU2018255935 A AU 2018255935A AU 2018255935 A AU2018255935 A AU 2018255935A AU 2018255935 B2 AU2018255935 B2 AU 2018255935B2
Authority
AU
Australia
Prior art keywords
compound
treatment
prophylaxis
pyrimidin
dihydro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018255935A
Other languages
English (en)
Other versions
AU2018255935A1 (en
Inventor
Bozena Ewa ADAMCZYK
Paul Anthony BAGULEY
Colin Thomas LINDLEY
Robert Craig MELLING
Michael Reader
Mark Henry SAUNDERS
Mirka SCARATI
Nicola Elizabeth WILSHER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Otsuka Pharmaceutical Co Ltd
Original Assignee
Otsuka Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharmaceutical Co Ltd filed Critical Otsuka Pharmaceutical Co Ltd
Publication of AU2018255935A1 publication Critical patent/AU2018255935A1/en
Application granted granted Critical
Publication of AU2018255935B2 publication Critical patent/AU2018255935B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2018255935A 2017-04-20 2018-04-20 6-pyrimidin-isoindole derivative as ERK1/2 inhibitor Active AU2018255935B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1706327.2A GB201706327D0 (en) 2017-04-20 2017-04-20 A pharmaceutical compound
GB1706327.2 2017-04-20
PCT/IB2018/052745 WO2018193410A1 (en) 2017-04-20 2018-04-20 6-pyrimidin-isoindole derivative as erk1/2 inhibitor

Publications (2)

Publication Number Publication Date
AU2018255935A1 AU2018255935A1 (en) 2019-11-07
AU2018255935B2 true AU2018255935B2 (en) 2022-03-17

Family

ID=58795788

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2018255935A Active AU2018255935B2 (en) 2017-04-20 2018-04-20 6-pyrimidin-isoindole derivative as ERK1/2 inhibitor

Country Status (21)

Country Link
US (3) US11142518B2 (enExample)
EP (1) EP3612524B1 (enExample)
JP (1) JP7113846B2 (enExample)
KR (1) KR102652193B1 (enExample)
CN (1) CN110831939B (enExample)
AU (1) AU2018255935B2 (enExample)
CA (1) CA3059674A1 (enExample)
DK (1) DK3612524T3 (enExample)
ES (1) ES2994283T3 (enExample)
FI (1) FI3612524T3 (enExample)
GB (1) GB201706327D0 (enExample)
IL (1) IL269803B (enExample)
MA (1) MA52123A (enExample)
MX (1) MX2019012471A (enExample)
MY (1) MY203722A (enExample)
PH (1) PH12019502154A1 (enExample)
SA (1) SA519410253B1 (enExample)
SG (1) SG11201909189QA (enExample)
TW (1) TWI813566B (enExample)
WO (1) WO2018193410A1 (enExample)
ZA (1) ZA201907484B (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL291017B2 (en) 2015-10-21 2023-11-01 Otsuka Pharma Co Ltd Benzolactam compounds as protein kinase inhibitors
GB201706327D0 (en) 2017-04-20 2017-06-07 Otsuka Pharma Co Ltd A pharmaceutical compound
JP7326305B2 (ja) 2018-03-02 2023-08-15 大塚製薬株式会社 医薬化合物
EP3827009A4 (en) 2018-07-24 2022-04-27 Taiho Pharmaceutical Co., Ltd. HETEROBICYCLIC COMPOUNDS TO INHIBIT SHP2 ACTIVITY
CN109608444B (zh) * 2018-11-27 2022-02-11 中国药科大学 含异吲哚啉酮的erk抑制剂及其制备方法与用途
GB201911928D0 (en) 2019-08-20 2019-10-02 Otsuka Pharma Co Ltd Pharmaceutical compounds
WO2021149817A1 (en) * 2020-01-24 2021-07-29 Taiho Pharmaceutical Co., Ltd. Enhancement of anti-tumor activity of SHP2 inhibitor pyrimidinone in combination with novel cancer medicines in cancers
WO2021218912A1 (zh) * 2020-04-30 2021-11-04 南京明德新药研发有限公司 含苯基并内磺酰胺的化合物
CN113967198A (zh) * 2020-07-24 2022-01-25 鲁南制药集团股份有限公司 一种甾体cyp17抑制剂胶囊及其制备方法
AU2021326929A1 (en) * 2020-08-21 2023-04-27 Shanghai Ringene Biopharma Co., Ltd. Aromatic ring-lactam compound, preparation method therefor and use thereof
KR20240021198A (ko) 2021-06-11 2024-02-16 오츠카 세이야쿠 가부시키가이샤 Erk 억제제의 제조 방법
WO2023059885A1 (en) * 2021-10-08 2023-04-13 Slayback Pharma Llc, Stable pharmaceutical compositions of cyclophosphamide
AU2022376165A1 (en) 2021-10-26 2024-05-16 Otsuka Pharmaceutical Co., Ltd. Compositions comprising an erk inhibitor
CN114085213B (zh) * 2022-01-20 2022-03-25 苏州国匡医药科技有限公司 一种arv-471的制备方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015108861A1 (en) * 2014-01-14 2015-07-23 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
WO2016025649A1 (en) * 2014-08-13 2016-02-18 Celgene Avilomics Research, Inc. Combinations of an erk inhibitor and a dot1l inhibitor and related methods
WO2017068412A1 (en) * 2015-10-21 2017-04-27 Otsuka Pharmaceutical Co., Ltd. Benzolactam compounds as protein kinase inhibitors

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5629327A (en) 1993-03-01 1997-05-13 Childrens Hospital Medical Center Corp. Methods and compositions for inhibition of angiogenesis
US5463063A (en) 1993-07-02 1995-10-31 Celgene Corporation Ring closure of N-phthaloylglutamines
US5958934A (en) 1996-05-23 1999-09-28 Syntex (U.S.A.) Inc. Aryl pyrimidine derivatives and uses thereof
JP2003504301A (ja) 1998-04-01 2003-02-04 ブリストル−マイヤーズ スクイブ ファーマ カンパニー インテグリンアンタゴニスト
HUP0402352A2 (hu) 2001-06-19 2005-02-28 Bristol-Myers Squibb Co. Foszfodiészteráz (PDE) 7 inhibitorként alkalmazható pirimidinszármazékok és ezeket tartalmazó gyógyszerkészítmények
ES2290743T3 (es) 2003-04-30 2008-02-16 The Institutes For Pharmaceutical Discovery, Llc Heteroarilos sustituidos como inhibidores de las proteina-tirosina fosfatasas.
US8362017B2 (en) 2003-08-29 2013-01-29 Exelixis, Inc. C-kit modulators and methods of use
US7504401B2 (en) 2003-08-29 2009-03-17 Locus Pharmaceuticals, Inc. Anti-cancer agents and uses thereof
EP3305776B1 (en) 2004-05-14 2019-09-25 Vertex Pharmaceuticals Incorporated Pyrrole compounds as inhibitors of erk protein kinases and pharmaceutical compositions containing these compounds
US20060235036A1 (en) 2005-04-15 2006-10-19 Doherty Elizabeth M Vanilloid receptor ligands and their use in treatments
CA2633023C (en) 2005-12-13 2015-11-24 Schering Corporation Polycyclic indazole derivatives that are erk inhibitors
US20080280891A1 (en) 2006-06-27 2008-11-13 Locus Pharmaceuticals, Inc. Anti-cancer agents and uses thereof
JP2009542604A (ja) 2006-07-06 2009-12-03 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ４−ヘテロシクロアルキルピリミジン、それらの調製方法及び医薬としての使用
WO2008008059A1 (en) 2006-07-12 2008-01-17 Locus Pharmaceuticals, Inc. Anti-cancer agents ans uses thereof
WO2008124085A2 (en) 2007-04-03 2008-10-16 Exelixis, Inc. Methods of using combinations of mek and jak-2 inhibitors
WO2009017838A2 (en) 2007-08-01 2009-02-05 Exelixis, Inc. Combinations of jak-2 inhibitors and other agents
WO2009039635A1 (en) 2007-09-24 2009-04-02 Painceptor Pharma Corporation Methods of modulating neurotrophin-mediated activity
WO2009042907A1 (en) 2007-09-27 2009-04-02 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Isoindoline compounds for the treatment of spinal muscular atrophy and other uses
CN101925596B (zh) 2008-01-24 2014-05-28 默克专利有限公司 用于治疗糖尿病的β-氨基酸衍生物
TWI458721B (zh) 2008-06-27 2014-11-01 Celgene Avilomics Res Inc 雜芳基化合物及其用途
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
GB0815369D0 (en) 2008-08-22 2008-10-01 Summit Corp Plc Compounds for treatment of duchenne muscular dystrophy
TWI453207B (zh) 2008-09-08 2014-09-21 Signal Pharm Llc 胺基三唑并吡啶，其組合物及使用其之治療方法
GB0821307D0 (en) 2008-11-21 2008-12-31 Summit Corp Plc Compounds for treatment of duchenne muscular dystrophy
SG171815A1 (en) 2008-12-19 2011-07-28 Bristol Myers Squibb Co Carbazole carboxamide compounds useful as kinase inhibitors
WO2010131922A2 (en) 2009-05-15 2010-11-18 Korea Research Institute Of Chemical Technology Amide compound, preparation method thereof and pharmaceutical composition comprising same
WO2010151747A1 (en) 2009-06-26 2010-12-29 Cystic Fibrosis Foundation Therapeutics, Inc. Pyrimine compounds and methods of making and using same
WO2011008931A2 (en) 2009-07-15 2011-01-20 Cystic Fibrosis Foundation Therapeutics, Inc. Arylpyrimidine compounds and combination therapy comprising same for treating cystic fibrosis & related disorders
ES2842399T3 (es) 2009-12-22 2021-07-14 Vertex Pharma Inhibidores isoindolinona de fosfatidilinositol 3-quinasa
AU2010336027A1 (en) 2009-12-23 2012-07-19 Auckland Uniservices Limited Compounds, preparations and uses thereof
NZ601526A (en) 2009-12-31 2014-07-25 Piramal Entpr Ltd Inhibitors of diacylglycerol acyl transferase
WO2012002527A1 (ja) 2010-07-02 2012-01-05 あすか製薬株式会社 複素環化合物及びｐ２７Ｋｉｐ１分解阻害剤
AU2011283684B2 (en) 2010-07-29 2015-08-27 Rigel Pharmaceuticals, Inc. AMPK-activating heterocyclic compounds and methods for using the same
US9938269B2 (en) 2011-06-30 2018-04-10 Abbvie Inc. Inhibitor compounds of phosphodiesterase type 10A
AU2013225737B2 (en) 2012-03-01 2018-03-01 Array Biopharma Inc. Serine/threonine kinase inhibitors
CN104583195B (zh) 2012-09-12 2018-08-17 山东亨利医药科技有限责任公司 作为酪氨酸激酶抑制剂的含氮杂芳环衍生物
US20150272939A1 (en) 2012-10-02 2015-10-01 Yale University Identification of Small Molecule Inhibitors of Jumonji AT-Rich Interactive Domain 1A (JARID1A) and 1B (JARID1B) Histone Demethylase
LT2914296T (lt) 2012-11-01 2018-09-25 Infinity Pharmaceuticals, Inc. Vėžio gydymas, panaudojant p13 kinazės izoformos moduliatorius
EP2953457B1 (en) 2013-02-08 2020-04-08 Celgene CAR LLC Erk inhibitors and uses thereof
WO2014130856A2 (en) 2013-02-21 2014-08-28 Wayne Rothbaum Treatment of skeletal-related disorders
TWI692477B (zh) 2013-08-30 2020-05-01 美商Ｐｔｃ治療公司 經取代嘧啶ｂｍｉ-１抑制劑
US20150087673A1 (en) 2013-09-26 2015-03-26 Rigel Pharmaceuticals, Inc. Methods for using and biomarkers for ampk-activating compounds
CA2944669A1 (en) 2014-04-04 2015-10-08 Syros Pharmaceuticals, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
US11311541B2 (en) 2014-04-09 2022-04-26 Kadmon Corporation, Llc Treatment of GVHD
TWI704151B (zh) 2014-12-22 2020-09-11 美商美國禮來大藥廠 Ｅｒｋ抑制劑
WO2016162325A1 (en) 2015-04-07 2016-10-13 Astrazeneca Ab Substituted 3,4-dihydropyrrolo[1,2-a]pyrazin-1 (2h)-one derivatives as kinase inhibitors
FI3307727T3 (fi) 2015-06-15 2024-01-08 Asana Biosciences Llc Erk1:n ja erk2:n heterosyklisiä estäjiä ja niiden käyttö syövän hoidossa
SI3374359T1 (sl) 2015-11-09 2020-04-30 Astrazeneca Ab Derivati dihidroimidazopirazinona uporabni pri zdravljenju raka
EP3492462B1 (en) 2016-07-26 2023-08-30 Shenzhen TargetRx, Inc. Amino pyrimidine compound for inhibiting protein tyrosine kinase activity
GB201706327D0 (en) 2017-04-20 2017-06-07 Otsuka Pharma Co Ltd A pharmaceutical compound

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015108861A1 (en) * 2014-01-14 2015-07-23 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
WO2016025649A1 (en) * 2014-08-13 2016-02-18 Celgene Avilomics Research, Inc. Combinations of an erk inhibitor and a dot1l inhibitor and related methods
WO2017068412A1 (en) * 2015-10-21 2017-04-27 Otsuka Pharmaceutical Co., Ltd. Benzolactam compounds as protein kinase inhibitors

Also Published As

Publication number Publication date
US20210101889A1 (en) 2021-04-08
RU2019135029A3 (enExample) 2021-07-16
TWI813566B (zh) 2023-09-01
US11142518B2 (en) 2021-10-12
BR112019019948A2 (pt) 2020-04-28
IL269803B (en) 2022-09-01
KR20190140957A (ko) 2019-12-20
SA519410253B1 (ar) 2023-07-12
MA52123A (fr) 2020-02-26
US20220169638A1 (en) 2022-06-02
US20250002481A1 (en) 2025-01-02
KR102652193B1 (ko) 2024-03-29
WO2018193410A1 (en) 2018-10-25
IL269803A (en) 2019-11-28
TW201842912A (zh) 2018-12-16
AU2018255935A1 (en) 2019-11-07
MY203722A (en) 2024-07-16
RU2019135029A (ru) 2021-05-20
EP3612524B1 (en) 2024-08-28
US12030873B2 (en) 2024-07-09
JP7113846B2 (ja) 2022-08-05
DK3612524T3 (da) 2024-09-30
CN110831939A (zh) 2020-02-21
EP3612524A1 (en) 2020-02-26
ES2994283T3 (en) 2025-01-21
MX2019012471A (es) 2019-12-11
JP2020517598A (ja) 2020-06-18
CA3059674A1 (en) 2018-10-25
CN110831939B (zh) 2025-05-09
PH12019502154A1 (en) 2020-06-29
SG11201909189QA (en) 2019-10-30
FI3612524T3 (fi) 2024-09-24
GB201706327D0 (en) 2017-06-07
NZ758411A (en) 2024-10-25
ZA201907484B (en) 2024-05-30

Similar Documents

Publication Publication Date Title
US12030873B2 (en) 6-pyrimidin-isoindole derivative as ERK1/2 inhibitor
JP7698629B2 (ja) ピラゾロ［３，４－ｂ］ピラジンｓｈｐ２ホスファターゼ阻害剤
JP7291839B2 (ja) 固体形態のｃｄｋ４阻害薬
CA3149119A1 (en) Deuterated compounds for use in the treatment of cancer
US20240166623A1 (en) Novel process
EP2909197A1 (en) Bicyclic heterocycle compounds and their uses in therapy
WO2018178691A1 (en) Isoindolinone inhibitors of the mdm2-p53 interaction and process for making them
CA3233255A1 (en) Heterocyclic compounds for use in the treatment of cancer
WO2015004481A1 (en) Imidazo-condensed bicycles as inhibitors of discoidin domain receptors (ddrs)
JP2022058085A (ja) ジアシルグリセロールアシルトランスフェラーゼ２阻害剤とアセチル－ＣｏＡカルボキシラーゼ阻害剤との組合せ
RU2786994C2 (ru) Фармацевтическое соединение
HK40023945B (en) 6-pyrimidin-isoindole derivative as erk1/2 inhibitor
HK40023945A (en) 6-pyrimidin-isoindole derivative as erk1/2 inhibitor
BR112019019948B1 (pt) Forma cristalina de derivado de 6-pirimidina-isoindol, seu processo de produção, sal amorfo, composição farmacêutica, e seus usos para fabricação de um medicamento

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)